Provided herein are pharmaceutical compositions comprising compounds that inhibit Factor XIa or kallikrein and methods of use thereof.

A prosthetic tissue valve and a method of treating the prosthetic tissue valve are provided. The method includes: decreasing a temperature of a chamber carrying the prosthetic tissue valve from a first preset temperature to a second preset temperature in a first cooling rate; decreasing the temperature of the chamber carrying the prosthetic tissue valve from the second preset temperature to a third preset temperature in a second cooling rate; and performing a drying process to the prosthetic tissue valve. The second preset temperature is a critical crystallization temperature and is greater than a crystallization temperature of the prosthetic tissue valve. The third preset temperature is lower than the crystallization temperature of the prosthetic tissue valve, and the second cooling rate is greater than the first cooling rate.

Embodiments herein relate to thromboresistant coatings, coated devices, and related methods. In an embodiment, a thromboresistant implantable, partially implantable, or wearable medical device is included having a substrate, a non-fouling basecoat layer, and a lubricious topcoat layer. The non-fouling basecoat layer can include a hydrophilic component and a hydrophobic component. The non-fouling basecoat layer is disposed over the substrate. The lubricious topcoat layer can include a photo-reactive polyvinylpyrrolidone compound and a cross-linking agent. The lubricious topcoat layer can be disposed over the non-fouling basecoat layer. Other embodiments are also included herein.

Medical devices, systems, and methods for treating conditions using antithrombin-heparin conjugates are disclosed. For example, medical devices can be coated with antithrombin-heparin (ATH) resulting in reduced thrombogenicity. Various conditions can likewise be treated with ATH.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Antimicrobial and antithrombogenic polymer or polymeric blend, compounds, coatings, and materials containing the same, as well as articles made with, or coated with the same, and methods of making the same exhibiting improved antimicrobial properties and reduced platelet adhesion. Embodiments include polymers with antimicrobial and antithrombogenic groups bound to a single polymer backbone, an antimicrobial polymer blended with an antithrombogenic polymer, and medical devices coated with the antimicrobial and antithrombogenic polymer or polymeric blend.

Artificial heart valve structures and methods of their fabrication are disclosed. The heart valve structures may be fabricated from a biocompatible polymer and include one or more heart valve leaflet structures incorporated within a conduit. The valve structures may incorporate one or more conduit sinuses, as well as a gap between the lower margin of the valve leaflets and the interior of the conduit. In addition, the valve structures may include one or more valve sinuses created in a space between the valve leaflets and the conduit inner surface. Computational fluid dynamics and mechanical modeling may be used to design the valve leaflets with optimal characteristics. A heart valve structure may also incorporate a biodegradable component to which cells may adhere. The incorporated cells may arise from patient cells migrating to the biodegradable component, or the component may be pre-seeded with cells prior to implantation in a patient.

Disclosed herein implantable material and methods for treatment of growth plate injuries and other purposes. These materials can be particularly useful for treating children whose growth plates are active, and can help encourage proper healing and inhibit unwanted bone formations. Exemplary compositions can comprise poly (ethylene glycol) (“PEG”), gelatin (“GEL”), and heparin (“HEP”). The PEG, GEL, and HEP components can be present in various forms of these materials, such as methacrylated forms, etc. The implanted materials can be anti-osteogenic and/or ant-mineralization, and can help prevent unwanted bone growth in the implanted area, such as boney tethers, which can inhibit desirable growth plate healing and overall bone growth.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.

This invention relates to the design and function of a compressible valve replacement prosthesis, collared or uncollared, which can be deployed into a beating heart without extracorporeal circulation using a transcatheter delivery system. The design as discussed focuses on the deployment of a device via a minimally invasive fashion and by way of example considers a minimally invasive surgical procedure preferably utilizing the intercostal or subxyphoid space for valve introduction. In order to accomplish this, the valve is formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the annulus of a target valve such as a mitral valve or tricuspid valve.